Details of Disease

General Information of Disease (ID: DIS7SN6U)

• Disease Name: Hypertriglyceridemia
• Synonyms: hypertriglyceridemia; hypertriglyceridemia (disease)
• Disease Class: 5C80: Hyper-lipoproteinaemia
• Definition: A laboratory test result indicating elevated triglyceride concentration in the blood.
• Disease Hierarchy:
  DIS71G5H: Metabolic disorder
  DIS7SN6U: Hypertriglyceridemia
• ICD Code:
  ICD-11: ICD-11: 5C80.1
  ICD-10: ICD-10: E78.1, E78.3
  ICD-9: ICD-9: 272.1, 427
  Expand ICD-11: '5C80.1
  Expand ICD-10: 'E78.1; 'E78.3
  Expand ICD-9: 272.1,427
• Disease Identifiers:
  MONDO ID: MONDO_0005347
  UMLS CUI: C0813230
  MedGen ID: 167238
  HPO ID: HP:0002155
  SNOMED CT ID: 166848004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 13 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atorvastatin	DMF28YC	Approved	Small molecular drug	[1]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Approved	Small molecular drug	[2]
Epanova	DMHEAGL	Approved	Small molecular drug	[3]
Fenofibrate	DMFKXDY	Approved	Small molecular drug	[4]
Icosapent	DMJHN0A	Approved	Small molecular drug	[5]
Lovastatin	DM9OZWQ	Approved	Small molecular drug	[6]
Mega-3-acid ethyl esters	DMECTMB	Approved	Small molecular drug	[3]
Pravastatin	DM6A0X7	Approved	Small molecular drug	[7]
Rosuvastatin	DMMIQ7G	Approved	Small molecular drug	[8]
Simvastatin	DM30SGU	Approved	Small molecular drug	[9]
Topiramate	DM82Z30	Approved	Small molecular drug	[10]
Vitamin B3	DMQVRZH	Approved	Small molecular drug	[11]
Volanesorsen	DM1YEPS	Approved	Antisense oligonucleotide	[12]

This Disease is Treated as An Indication in 13 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ARO-APOC3	DMABKHH	Phase 3	RNA interference	[13]
LCQ908	DMFLJHQ	Phase 3	Small molecular drug	[14]
Olezarsen	DMNLSFN	Phase 3	Antisense oligonucleotide	[15]
Pegozafermin	DM5D7VG	Phase 3	NA	[16]
Icosapent ethyl	DMKI68F	Phase 2/3	Small molecule	[17]
AKCEA-APOCIII-LRX	DMJ7FI0	Phase 2	NA	[18]
ARI-3037MO	DM9LNXS	Phase 2	NA	[18]
CaPre	DMH0FMN	Phase 2	NA	[18]
CAT-2003	DMCVC0H	Phase 2	NA	[19]
Epeleuton	DMJ1YQ2	Phase 2	Small molecule	[20]
Gemcabene	DMEVAOB	Phase 2	NA	[18]
Vupanorsen	DMN6J18	Phase 2	Antisense oligonucleotide	[21]
GS 9667	DMI319T	Phase 1	Small molecular drug	[22]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AS-1708727	DM6MWDH	Investigative	NA	[23]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
LIPI	OTSO833D	Limited	Autosomal dominant	[24]
CREB3L3	OTDMU3GP	Strong	Autosomal dominant	[24]
GPIHBP1	OTDF8R2M	Strong	CausalMutation	[25]

References

• [1] Atorvastatin FDA Label
• [2] FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridemia
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Fenofibrate FDA Label
• [5] ClinicalTrials.gov (NCT01047683) Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels 500 and 2000 mg/dL. U.S. National Institutes of Health.
• [6] Lovastatin FDA Label
• [7] Pravastatin FDA Label
• [8] Rosuvastatin FDA Label
• [9] Simvastatin FDA Label
• [10] Topiramate FDA Label
• [11] Niacin: chemical forms, bioavailability, and health effects. Nutr Rev. 2012 Jun;70(6):357-66.
• [12] Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173.
• [13] ClinicalTrials.gov (NCT04720534) A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia. U.S.National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] ClinicalTrials.gov (NCT05681351) An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). U.S.National Institutes of Health.
• [16] ClinicalTrials.gov (NCT05852431) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study. U.S.National Institutes of Health.
• [17] Icosapent ethyl FDA Label
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] ClinicalTrials.gov (NCT01912560) Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT04365400) A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes. U.S.National Institutes of Health.
• [21] ClinicalTrials.gov (NCT03371355) Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. U.S. National Institutes of Health.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5593).
• [23] Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91.
• [24] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [25] Whole-exome sequencing reveals GPIHBP1 mutations in infantile colitis with severe hypertriglyceridemia.J Pediatr Gastroenterol Nutr. 2014 Jul;59(1):17-21. doi: 10.1097/MPG.0000000000000363.